
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Clinical features, treatment and prognosis analysis of distant metastatic esophageal cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE532E428AF21CA3052E420005DA5B29.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="scirep">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Scientific Reports">
<meta name="citation_title" content="Clinical features, treatment and prognosis analysis of distant metastatic esophageal cancer">
<meta name="citation_author" content="Shuang Li">
<meta name="citation_author_institution" content="Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Yanwei Lu">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Ruiqi Liu">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Luanluan Huang">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Ding Nan">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Xiaoyan Chen">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Wenjie Xia">
<meta name="citation_author_institution" content="General Surgery, Cancer Center, Department of Breast Surgery, Affiliated People’s Hospital, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Xiaodong Liang">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_author" content="Haibo Zhang">
<meta name="citation_author_institution" content="Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="15">
<meta name="citation_firstpage" content="30977">
<meta name="citation_doi" content="10.1038/s41598-025-16890-w">
<meta name="citation_pmid" content="40846774">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/pdf/41598_2025_Article_16890.pdf">
<meta name="description" content="Esophageal cancer (EC) is one of the most common malignant tumors in China. EC is characterized by a poor clinical prognosis, with many patients being diagnosed at advanced stages. This study utilized data from the Surveillance, Epidemiology, and ...">
<meta name="og:title" content="Clinical features, treatment and prognosis analysis of distant metastatic esophageal cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Esophageal cancer (EC) is one of the most common malignant tumors in China. EC is characterized by a poor clinical prognosis, with many patients being diagnosed at advanced stages. This study utilized data from the Surveillance, Epidemiology, and ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12373775">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41598-025-16890-w"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41598_2025_Article_16890.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12373775%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12373775/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12373775/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-scirep.jpg" alt="Scientific Reports logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Scientific Reports" title="Link to Scientific Reports" shape="default" href="http://www.nature.com/srep" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sci Rep</button></div>. 2025 Aug 22;15:30977. doi: <a href="https://doi.org/10.1038/s41598-025-16890-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41598-025-16890-w</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci%20Rep%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci%20Rep%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Clinical features, treatment and prognosis analysis of distant metastatic esophageal cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Shuang Li</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Shuang Li</span></h3>
<div class="p">
<sup>1</sup>Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shuang Li</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lu%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Yanwei Lu</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Yanwei Lu</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lu%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yanwei Lu</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ruiqi Liu</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ruiqi Liu</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ruiqi Liu</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Luanluan Huang</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Luanluan Huang</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Luanluan Huang</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nan%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ding Nan</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ding Nan</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nan%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Ding Nan</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Xiaoyan Chen</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Xiaoyan Chen</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyan Chen</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xia%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Wenjie Xia</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Wenjie Xia</span></h3>
<div class="p">
<sup>3</sup>General Surgery, Cancer Center, Department of Breast Surgery, Affiliated People’s Hospital, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Xia%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wenjie Xia</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Xiaodong Liang</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Xiaodong Liang</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaodong Liang</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Haibo Zhang</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Haibo Zhang</span></h3>
<div class="p">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Haibo Zhang</span></a>
</div>
</div>
<sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div id="Aff2">
<sup>2</sup>Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) , Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div id="Aff3">
<sup>3</sup>General Surgery, Cancer Center, Department of Breast Surgery, Affiliated People’s Hospital, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Jul 1; Accepted 2025 Aug 20; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12373775  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40846774/" class="usa-link">40846774</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par1">Esophageal cancer (EC) is one of the most common malignant tumors in China. EC is characterized by a poor clinical prognosis, with many patients being diagnosed at advanced stages. This study utilized data from the Surveillance, Epidemiology, and End Results (SEER) database. The clinical features, treatment, and prognostic factors of patients with distant metastatic EC were screened and analyzed, and a nomogram was drawn to construct a predictive model. Eligible patients with distant metastatic EC diagnosed from January 2004 to December 2015 were extracted from the SEER database. Propensity score matching (PSM) was used to eliminate group baseline differences.The data were divided into the training cohort (1116 cases) and validation cohort (426 cases) by using R software and random sampling function at the ratio of 7:3. The baseline table was plotted using Chi-square test or Fisher’s exact test. Kaplan–Meier curve, log-rank test, and Cox regression were used for survival analysis. C-index and AUC were used to evaluate the performance of the prognosis model. The calibration curve was used to evaluate the calibration of the model. Using the data of the validation cohort, external validation is used to create a prediction model. After applying the inclusion and exclusion criteria and PSM, a total of 1542 cases diagnosed between 2004 and 2015 were included in the study. We analyzed the Kaplan–Meier survival of patients with metastatic EC before and after PSM, focusing on different treatment methods. The results indicated that radiotherapy, chemotherapy, and surgical treatment provided significant survival benefits to patients with metastatic EC(<em>P</em> &lt; 0.05). Univariate and Multivariate regression analysis showed that T-stage, M-stage, primary site, surgery, chemotherapy, and radiotherapy were independent prognostic factors affecting the prognosis of distant metastatic EC (<em>P</em> &lt; 0.05). Evaluating the predictive ability of the nomogram, the C index of the training cohort was 0.69 (95% CI 0.67–0.71), and the C-index of the validation cohort was 0.659 (95% CI 0.627–0.693)0.6606 patients met the inclusion criteria and were enrolled in the study’s external validation group. In this group, the AUC values of our external validation model for 1-, 2-, and 3-year overall survival (OS) were 0.775 (95% CI 0.762–0.787), 0.790 (95% CI 0.744–0.807). The C-index was 0.726. The AUC values for both the training and validation cohorts for the 1-year OS ranged from 0.50 to 0.70, and the AUC for the rest of the training and validation cohort ranged from 0.70 to 0.90, which suggests that the model is moderately discriminating. The calibration curves of 1 year, 2 years, and 3 years in the two groups are very close to the 45° reference line, suggesting that the models exhibit a good degree of calibration. The C-index, the AUC, and calibration curves suggest that the models have good discriminating and calibration. The results reveal that the T stage, M stage, primary tumor site, surgery, chemotherapy, and radiotherapy play an important role in influencing the treatment effect and prognosis of patients. The nomogram prediction model, which is based on these independent risk factors, shows good discriminative ability and calibration.</p>
<section id="sec1"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1038/s41598-025-16890-w.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Distant metastatic oesophageal cancer, PSM, SEER database, Prediction model</p></section><section id="kwd-group2" class="kwd-group"><p><strong>Subject terms:</strong> Cancer models, Cancer, Cancer, Diseases, Oncology</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par5">Esophageal cancer ranks seventh globally in cancer incidence and sixth in mortality<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a></sup>. EC was found to be the fourth leading cause of cancer deaths in Chinese men over the age of 45 in the National Cancer Center Registry in 2016<sup><a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup>. China has a high incidence of esophageal cancer, accounting for more than half of the global EC cases<sup><a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. The main histological subtype of EC is squamous cell carcinoma<sup><a href="#CR2" class="usa-link" aria-describedby="CR2">2</a></sup>. In 2020, the number of new cases of EC will reach 604,000, and the number of deaths will reach 544,000<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a></sup>. Esophageal cancer is an aggressive type of tumor, which is treated with surgery, chemotherapy, radiotherapy, and various targeted therapies<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>. The 5-year survival remains low (20%). EC is usually diagnosed in the late stage, mainly due to the lack of early clinical symptoms. With the continuous progress of comprehensive treatment of esophageal cancer, the prognosis of EC has improved using endoscopic treatment, surgical techniques, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. Identifying, exploring, and intervening all potential risk factors may reduce the incidence of esophageal cancer. Risk factors for EC include gastroesophageal reflux disease, obesity, smoking, drinking hot tea and alcohol, eating pickles, low fruit intake, hot food drinks, malnutrition, and low socio-economic status<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>,<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a></sup>. Studies have shown that Barrett’s esophagus is also an important risk factor for esophageal cancer. The risk factors of esophageal squamous cell carcinoma and adenocarcinoma are still different<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup>. Therefore, identifying risk factors and establishing a prediction model can benefit patients. It can also help clinicians to make more appropriate medical decisions for patients.</p>
<p id="Par6">Studies have shown that concurrent chemoradiotherapy (CCRT) is the preferred treatment for unresectable locally advanced esophageal cancer<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a></sup>. Radiotherapy is one of the main cancer treatments<sup><a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>. At present, 5-fluorouracil or capecitabine combined with oxaliplatin or cisplatin is commonly used to treat locally advanced or metastatic esophageal squamous cell cancer<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a></sup>. One study found that definitive radiotherapy improved overall survival (OS) in newly diagnosed metastatic esophageal cancer<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup>. Short-term radiotherapy is used to relieve dysphagia, malnutrition, and chronic bleeding in esophageal cancer<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup>. Comprehensive treatment is crucial for managing esophageal cancer. Endoscopic therapy and surgical intervention are options for early-stage cancer. Chemotherapy, targeted drug therapy, and immunotherapy are used for the treatment of unresectable locally advanced or advanced patients. Currently, there are limited options for targeted therapy in esophageal cancer, mostly targeting human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and inositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR)<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup>. It is reported that adoptive T cell transfer technology is also used for distant metastatic esophageal cancer<sup><a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup>. Of course, it also needs a lot of clinical trial data to verify. Clinical trials such as KEYNOTE-590, CheckMate648, KEYNOTE-811, and ATTRACTION-3 demonstrate that immunotherapy can improve the prognosis of advanced EC patients.</p>
<p id="Par7">Preference score matching (PSM) is a statistical method to reduce data bias and the influence of confounding variables in observation and research. PSM is often used to balance baseline characteristics and eliminate the bias between the treatment population and the control population. The SEER database is a large tumor database established by the National Cancer Institute. It is a public database commonly used clinically for surveillance and research in the field of cancer. Nomograms are widely used for cancer prognosis.</p>
<p id="Par8">Nomograms are widely utilized in clinical care. They play a crucial role in predicting patient survival and informing clinical decision-making by physicians. For instance, one study used nomogram to evaluate the survival probability of patients with metastatic lung cancer who received radiotherapy for bone metastases<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>. This suggests that the use of a nomogram can assist radiation oncologists in tailoring treatment to a patient’s life expectancy, including the initiation of end-of-life discussions and hospice referrals when appropriate. The same principle applies to initiating hospice care for patients with distant metastatic esophageal cancer. Nomograms can provide valuable clinical treatment support with a degree of credibility.</p>
<p id="Par9">In recent years, there have been few prognostic models for patients with metastatic esophageal cancer. Metastatic EC is not clear in this field at present. The prognosis model has been constructed, which has a good prediction effect on patients with metastatic EC and also has certain clinical references.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patients and selection criteria</h3>
<p id="Par10">Patients with distant metastatic EC from January 2004 to December 2015 were selected from the SEER database. Data used in this research are publicly available to qualified researchers on application to the SEER database(<a href="https://seer.cancer.gov/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://seer.cancer.gov/</a>). Training cohort: Incidence-SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000–2018). External validation. Incidence-SEER Research Data, 17 Registries, Nov 2023 Sub (2000–2021).</p>
<p id="Par11">Patients with metastatic EC were identified based on the following inclusion criteria: From January 2004 to December 2015, patients with esophageal cancer classified as M1 stage according to the AJCC 6th edition were included. Patients must have complete survival time data, and the effectiveness of follow-up must be guaranteed; EC was diagnosed by pathology. The exclusion criteria: Patients with missing or insufficient information such as staging, survival rate, follow-up time, or cause of death; The treatment is not clear; The patient has not only one primary malignant tumor; The patients diagnosed only by autopsy results or death certificates. SEER database data is publicly available, so it does not need ethical approval.</p></section><section id="Sec25"><h3 class="pmc_sec_title">Ethical approval</h3>
<p id="Par12">was exempt from this retrospective study since SEER data are de-identified and publicly available for research use.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Study variables</h3>
<p id="Par13">The following patient information was collected: age, race, sex, primary site, histological type, degree of differentiation, TNM stage, radiotherapy, chemotherapy, surgery, survival time, survival status, and so on. The end point of our research is OS. OS was defined as the time from the start of diagnosis to the time of death from any cause or the time of the last follow-up cutoff.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Construction of the nomogram</h3>
<p id="Par14">After screening the data from the SEER database to meet the inclusion and exclusion criteria, baseline differences were eliminated by the PSM, and then the matched data were randomly divided into a training cohort and a validation cohort in a 7:3 ratio using the R software and plotted a baseline table for each variable. Kaplan–Meier method was used to draw the survival curves of the radiotherapy group and chemotherapy group. The log-rank test was used to compare the differences between OS. Univariate Cox regression model was used to analyze the prognostic factors of metastatic EC (<em>P</em> &lt; 0.05), The variables with <em>p</em> &lt; 0.05 were analyzed by multivariate Cox regression. The risk ratio (HR) and the corresponding 95% confidence interval (95%CI) are calculated. The index of independent risk factors for metastatic EC was obtained (<em>P</em>&lt;0.05). Based on these independent prognostic factors, we use R software to construct a nomogram, which can predict the probability of OS in patients with metastatic EC for 1 year, 2 years, and 3 years.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Discrimination and calibration of the nomogram</h3>
<p id="Par15">C-index and calibration curves are often used to evaluate the performance and accuracy of nomograms. The discrimination degree of the prediction model is the degree of evaluating the ability of the model to predict events. The degree of discrimination can reflect the prediction ability of constructing this prediction model. The nomogram was validated using C-index, AUC, and calibration curve. In the ROC curve, the abscissa is specificity, and the ordinate is sensitivity. C index and AUC of 0.5 indicate that the model has no predictive ability. The range of 0.50–0.70 indicates that the discrimination of the prediction model is low. A range of 0.70–0.90 indicates that the prediction discrimination is moderate. More than 0.90 indicates that the prediction model has high discrimination.</p>
<p id="Par16">Calibration degree, also called fitting degree, which can be evaluated by calibration curve to evaluate the degree of accurate risk estimation by the model. The higher the overlap of the model prediction curve with the diagonal standard line, the better the calibration of the model.</p></section></section><section id="Sec7"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec8"><h3 class="pmc_sec_title">Case inclusion and exclusion process</h3>
<p id="Par17">The inclusion and exclusion criteria of the study cases are shown in Fig. <a href="#Fig1" class="usa-link">1</a>. The study’s external validation group is shown in Supplementary Table <a href="#MOESM5" class="usa-link">1</a>. We selected patient cases from the SEER database between January 2004 and December 2015, and these patients were diagnosed with EC in a total of 10,792 cases. Patients with EC with M1 distant metastases were subsequently included. After that, we excluded patients with missing race (3 cases); patients with missing marital status (77 cases); patient cases with missing grading (388 cases); patient cases with missing tumor size (2165 cases); patients with incomplete information on TNM staging (1318 cases); and patients diagnosed only by autopsy results or death certificates (89 cases), which left 2068 patients. These patients were treated with radiotherapy in 1087 cases, and there were 981 patients who did not receive radiotherapy.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373775_41598_2025_16890_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b5/12373775/5608312816ed/41598_2025_16890_Fig1_HTML.jpg" loading="lazy" id="d33e374" height="379" width="669" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart of patients’ selection.</p></figcaption></figure></section></section><section id="Sec9"><h2 class="pmc_sec_title">Baseline characteristics</h2>
<p id="Par20">Table <a href="#Tab1" class="usa-link">1</a> shows the clinical baseline characteristics of all patients with metastatic esophageal cancer. From the analysis of the table, it can be seen that the number of patients in the radiotherapy group was 1087, the number of patients in the non-radiotherapy group was 981, and the number of patients receiving radiotherapy in metastatic EC accounted for 52.6% of the total number of patients. Before the use of PSM, it was possible to observe some differences in the distribution of some variables between the two groups, which included marital status, chemotherapy treatment, tumor location, surgical treatment, and degree of differentiation. The proportion of unmarried patients who received radiotherapy increased relative to those who did not receive radiotherapy; patients who received radiotherapy were more likely to receive chemotherapy and surgery; patients with upper and mid-stage EC were more likely to receive radiotherapy; and receipt of radiotherapy was increased in patients with lower levels of differentiation; of these, there were no statistically significant differences in the variables of gender, age, ethnicity, and histology on whether or not they received radiotherapy. By matching using the PSM method, we categorized patients into a group that did not receive radiotherapy and a group that received radiotherapy, each including 771 patients. By analyzing the baseline characteristics of the two groups, we can observe that there is no statistically significant difference in the data of patients who received radiotherapy or not after matching by the PSM method, and the data after balancing for the same variable satisfy <em>P</em> &gt; 0.05, which indicates that PSM has well balanced the baseline characteristics between the group that received radiotherapy and the group that did not receive radiotherapy. With this method, we eliminated the interference of confounding factors on the study results during the research process and improved the reliability of the study results.</p>
<section class="tw xbox font-sm" id="Tab1"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Clinical characteristics before and after PSM according to radiotherapy or not.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Variables</th>
<th align="left" colspan="2" rowspan="1">Before matching</th>
<th align="left" rowspan="2" colspan="1">
<em>P</em><sup>a</sup> value</th>
<th align="left" colspan="2" rowspan="1">After matching</th>
<th align="left" rowspan="2" colspan="1">
<em>P</em> value</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Non-radiotherapy <em>N</em> = 981(%)</th>
<th align="left" colspan="1" rowspan="1">Radiotherapy <em>N</em> = 1087 (%)</th>
<th align="left" colspan="1" rowspan="1">Non- radiotherapy <em>N</em> = 771(%)</th>
<th align="left" colspan="1" rowspan="1">Radiotherapy <em>N</em> = 771(%)</th>
</tr>
</thead>
<tbody>
<tr><td align="left" colspan="7" rowspan="1">Sex</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Male</td>
<td align="center" colspan="1" rowspan="1">811 (82.7%)</td>
<td align="center" colspan="1" rowspan="1">907 (83.4%)</td>
<td align="left" rowspan="2" colspan="1">0.684</td>
<td align="center" colspan="1" rowspan="1">644 (83.5%)</td>
<td align="center" colspan="1" rowspan="1">644 (83.5%)</td>
<td align="left" rowspan="2" colspan="1">1.000</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Female</td>
<td align="center" colspan="1" rowspan="1">170 (17.3%)</td>
<td align="center" colspan="1" rowspan="1">180 (16.6%)</td>
<td align="center" colspan="1" rowspan="1">127 (16.5%)</td>
<td align="center" colspan="1" rowspan="1">127 (16.5%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Age</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  &lt; 65 years</td>
<td align="center" colspan="1" rowspan="1">539 (54.9%)</td>
<td align="center" colspan="1" rowspan="1">618 (56.9%)</td>
<td align="left" rowspan="2" colspan="1">0.407</td>
<td align="center" colspan="1" rowspan="1">435 (56.4%)</td>
<td align="center" colspan="1" rowspan="1">442 (57.3%)</td>
<td align="left" rowspan="2" colspan="1">0.758</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  ≥ 65 years</td>
<td align="center" colspan="1" rowspan="1">442 (45.1%)</td>
<td align="center" colspan="1" rowspan="1">469 (43.1%)</td>
<td align="center" colspan="1" rowspan="1">336 (43.6%)</td>
<td align="center" colspan="1" rowspan="1">329 (42.7%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Race</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  White</td>
<td align="center" colspan="1" rowspan="1">810 (82.6%)</td>
<td align="center" colspan="1" rowspan="1">868 (79.9%)</td>
<td align="left" rowspan="2" colspan="1">0.128</td>
<td align="center" colspan="1" rowspan="1">642 (83.3%)</td>
<td align="center" colspan="1" rowspan="1">632 (82.0%)</td>
<td align="left" rowspan="2" colspan="1">0.545</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Unwhite</td>
<td align="center" colspan="1" rowspan="1">171 (17.4%)</td>
<td align="center" colspan="1" rowspan="1">219 (20.1%)</td>
<td align="center" colspan="1" rowspan="1">129 (16.7%)</td>
<td align="center" colspan="1" rowspan="1">139 (18.0%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Marriage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Married</td>
<td align="center" colspan="1" rowspan="1">458 (46.7%)</td>
<td align="center" colspan="1" rowspan="1">440 (40.5%)</td>
<td align="left" rowspan="2" colspan="1">0.005</td>
<td align="center" colspan="1" rowspan="1">429 (55.6%)</td>
<td align="center" colspan="1" rowspan="1">432 (56.0%)</td>
<td align="left" rowspan="2" colspan="1">0.918</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Unmarried</td>
<td align="center" colspan="1" rowspan="1">523 (53.3%)</td>
<td align="center" colspan="1" rowspan="1">647 (59.5%)</td>
<td align="center" colspan="1" rowspan="1">342 (44.4%)</td>
<td align="center" colspan="1" rowspan="1">339 (44.0%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  None</td>
<td align="center" colspan="1" rowspan="1">429 (43.7%)</td>
<td align="center" colspan="1" rowspan="1">229 (21.1%)</td>
<td align="left" rowspan="2" colspan="1">&lt; 0.001</td>
<td align="center" colspan="1" rowspan="1">252 (32.7%)</td>
<td align="center" colspan="1" rowspan="1">226 (29.3%)</td>
<td align="left" rowspan="2" colspan="1">0.169</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Yes</td>
<td align="center" colspan="1" rowspan="1">552 (56.3%)</td>
<td align="center" colspan="1" rowspan="1">858 (78.9%)</td>
<td align="center" colspan="1" rowspan="1">519 (67.3%)</td>
<td align="center" colspan="1" rowspan="1">545 (70.7%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Primary site</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Cervical/Upper</td>
<td align="center" colspan="1" rowspan="1">36 (3.7%)</td>
<td align="center" colspan="1" rowspan="1">65 (6.0%)</td>
<td align="left" rowspan="4" colspan="1">&lt; 0.001</td>
<td align="center" colspan="1" rowspan="1">31 (4.0%)</td>
<td align="center" colspan="1" rowspan="1">30 (3.9%)</td>
<td align="left" rowspan="4" colspan="1">0.667</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Thoracic/middle</td>
<td align="center" colspan="1" rowspan="1">170 (17.3%)</td>
<td align="center" colspan="1" rowspan="1">207 (19.0%)</td>
<td align="center" colspan="1" rowspan="1">142 (18.4%)</td>
<td align="center" colspan="1" rowspan="1">137 (17.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Abdominal/lower</td>
<td align="center" colspan="1" rowspan="1">699 (71.3%)</td>
<td align="center" colspan="1" rowspan="1">768 (70.7%)</td>
<td align="center" colspan="1" rowspan="1">558 (72.4%)</td>
<td align="center" colspan="1" rowspan="1">561 (72.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Overlapping</td>
<td align="center" colspan="1" rowspan="1">76 (7.7%)</td>
<td align="center" colspan="1" rowspan="1">47 (4.3%)</td>
<td align="center" colspan="1" rowspan="1">40 (5.2%)</td>
<td align="center" colspan="1" rowspan="1">43 (5.6%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Histology</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Adenocarcinoma</td>
<td align="center" colspan="1" rowspan="1">652 (66.5%)</td>
<td align="center" colspan="1" rowspan="1">684 (62.9%)</td>
<td align="left" rowspan="2" colspan="1">0.102</td>
<td align="center" colspan="1" rowspan="1">516 (66.9%)</td>
<td align="center" colspan="1" rowspan="1">516 (66.9%)</td>
<td align="left" rowspan="2" colspan="1">1.000</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Non-adenocarcinoma</td>
<td align="center" colspan="1" rowspan="1">329 (33.5%)</td>
<td align="center" colspan="1" rowspan="1">403 (37.1%)</td>
<td align="center" colspan="1" rowspan="1">255 (33.1%)</td>
<td align="center" colspan="1" rowspan="1">255 (33.1%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Surgery</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  None</td>
<td align="center" colspan="1" rowspan="1">928 (94.6%)</td>
<td align="center" colspan="1" rowspan="1">977 (89.9%)</td>
<td align="left" rowspan="2" colspan="1">&lt; 0.001</td>
<td align="center" colspan="1" rowspan="1">726 (94.2%)</td>
<td align="center" colspan="1" rowspan="1">733 (95.1%)</td>
<td align="left" rowspan="2" colspan="1">0.498</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Yes</td>
<td align="center" colspan="1" rowspan="1">53 (5.4%)</td>
<td align="center" colspan="1" rowspan="1">110 (10.1%)</td>
<td align="center" colspan="1" rowspan="1">45 (5.8%)</td>
<td align="center" colspan="1" rowspan="1">38 (4.9%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Grade</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">I   + II</td>
<td align="center" colspan="1" rowspan="1">336 (34.3%)</td>
<td align="center" colspan="1" rowspan="1">447 (41.1%)</td>
<td align="left" rowspan="2" colspan="1">0.002</td>
<td align="center" colspan="1" rowspan="1">280 (36.3%)</td>
<td align="center" colspan="1" rowspan="1">272 (35.3%)</td>
<td align="left" rowspan="2" colspan="1">0.710</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  III + IV</td>
<td align="center" colspan="1" rowspan="1">645(65.7%)</td>
<td align="center" colspan="1" rowspan="1">640 (58.9%)</td>
<td align="center" colspan="1" rowspan="1">491 (63.7%)</td>
<td align="center" colspan="1" rowspan="1">499 (64.7%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">T Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T1</td>
<td align="center" colspan="1" rowspan="1">284(29.0%)</td>
<td align="center" colspan="1" rowspan="1">244 (22.4%)</td>
<td align="left" rowspan="5" colspan="1">0.950</td>
<td align="center" colspan="1" rowspan="1">217 (28.1%)</td>
<td align="center" colspan="1" rowspan="1">197 (25.6%)</td>
<td align="left" rowspan="5" colspan="1">0.817</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T2</td>
<td align="center" colspan="1" rowspan="1">50 (5.1%)</td>
<td align="center" colspan="1" rowspan="1">70 (6.4%)</td>
<td align="center" colspan="1" rowspan="1">37 (4.8%)</td>
<td align="center" colspan="1" rowspan="1">47 (6.1%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T3</td>
<td align="center" colspan="1" rowspan="1">208 (21.2%)</td>
<td align="center" colspan="1" rowspan="1">361 (33.2%)</td>
<td align="center" colspan="1" rowspan="1">176 (22.8%)</td>
<td align="center" colspan="1" rowspan="1">214 (27.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T4</td>
<td align="center" colspan="1" rowspan="1">253 (25.8%)</td>
<td align="center" colspan="1" rowspan="1">254 (23.4%)</td>
<td align="center" colspan="1" rowspan="1">206 (26.7%)</td>
<td align="center" colspan="1" rowspan="1">193 (25.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Tx</td>
<td align="center" colspan="1" rowspan="1">186 (19.0%)</td>
<td align="center" colspan="1" rowspan="1">158 (14.5%)</td>
<td align="center" colspan="1" rowspan="1">135 (17.5%)</td>
<td align="center" colspan="1" rowspan="1">120 (15.6%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">N Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  N0</td>
<td align="center" colspan="1" rowspan="1">268 (27.3%)</td>
<td align="center" colspan="1" rowspan="1">288 (26.5%)</td>
<td align="left" rowspan="3" colspan="1">0.076</td>
<td align="center" colspan="1" rowspan="1">211 (27.4%)</td>
<td align="center" colspan="1" rowspan="1">206 (26.7%)</td>
<td align="left" rowspan="3" colspan="1">0.652</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  N1</td>
<td align="center" colspan="1" rowspan="1">600 (61.2%)</td>
<td align="center" colspan="1" rowspan="1">731 (67.2%)</td>
<td align="center" colspan="1" rowspan="1">489 (63.4%)</td>
<td align="center" colspan="1" rowspan="1">509 (66.0%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Nx</td>
<td align="center" colspan="1" rowspan="1">113 (11.5%)</td>
<td align="center" colspan="1" rowspan="1">68 (6.3%)</td>
<td align="center" colspan="1" rowspan="1">71 (9.2%)</td>
<td align="center" colspan="1" rowspan="1">56 (7.3%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">M Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  M1a</td>
<td align="center" colspan="1" rowspan="1">44 (4.5%)</td>
<td align="center" colspan="1" rowspan="1">150 (13.8%)</td>
<td align="left" rowspan="2" colspan="1">&lt; 0.001</td>
<td align="center" colspan="1" rowspan="1">43 (5.6%)</td>
<td align="center" colspan="1" rowspan="1">31 (4.0%)</td>
<td align="left" rowspan="2" colspan="1">0.190</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  M1b</td>
<td align="center" colspan="1" rowspan="1">937 (95.5%)</td>
<td align="center" colspan="1" rowspan="1">937 (86.2%)</td>
<td align="center" colspan="1" rowspan="1">728 (94.4%)</td>
<td align="center" colspan="1" rowspan="1">740 (96.0%)</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Vital status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Alive</td>
<td align="center" colspan="1" rowspan="1">20 (2.0%)</td>
<td align="center" colspan="1" rowspan="1">32 (2.9%)</td>
<td align="left" rowspan="2" colspan="1">0.189</td>
<td align="center" colspan="1" rowspan="1">15 (1.9%)</td>
<td align="center" colspan="1" rowspan="1">19 (2.5%)</td>
<td align="left" rowspan="2" colspan="1">0.488</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Death</td>
<td align="center" colspan="1" rowspan="1">961 (98.0%)</td>
<td align="center" colspan="1" rowspan="1">1055 (97.1%)</td>
<td align="center" colspan="1" rowspan="1">756 (98.1%)</td>
<td align="center" colspan="1" rowspan="1">752 (97.5%)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section id="Sec10"><h3 class="pmc_sec_title">Survival analyses</h3>
<p id="Par22">To further demonstrate the therapeutic effects of radiotherapy, chemotherapy, and surgery in patients with distant metastatic esophageal cancer, we grouped the patients according to whether they received radiotherapy, chemotherapy or not, or surgery or not, and then we performed Kaplan–Meier survival analysis of metastatic EC patients before and after PSM, and the specific results are detailed in Fig. <a href="#Fig2" class="usa-link">2</a>. Figure <a href="#Fig2" class="usa-link">2</a>A showed that the survival graph of metastatic EC patients before PSM, and there was a significant improvement in the chemotherapy group OS compared with no chemotherapy ([HR] 0.324, 95% CI 0.294 –0.358, <em>p</em> &lt; 0.0001). Figure <a href="#Fig2" class="usa-link">2</a>B shows the survival graph after PSM in patients with metastatic esophageal cancer, and there was a significant improvement in OS in the chemotherapy group compared with no chemotherapy ([HR] 0.369, 95% CI 0.330–0.413, <em>p</em> &lt; 0.0001). Figure <a href="#Fig2" class="usa-link">2</a>C shows the survival graph of metastatic EC patients before PSM, and there was a significant improvement in OS in the radiotherapy group compared with the no-radiotherapy group ([HR] 0.681, 95% CI 0.624–0.744, <em>p</em> &lt; 0.0001). Figure <a href="#Fig2" class="usa-link">2</a>D shows the survival graph of metastatic EC patients before PSM, and there was a significant improvement in OS in the radiotherapy group compared with no radiotherapy ([HR] 0.879, 95% CI 0.795–0.973, <em>p</em> = 0.0084). Figure <a href="#Fig2" class="usa-link">2</a>E shows the survival graph of metastatic EC patients before PSM, and there was a significant improvement in OS in the surgical group compared with the non-surgical group ([HR] 0.455, 95% CI 0.383–0.540, <em>p</em> &lt; 0.0001). Figure <a href="#Fig2" class="usa-link">2</a>F shows the survival graph after PSM in patients with metastatic esophageal cancer, and there was a significant improvement in OS in the surgical group compared with the non-surgical group ([HR] 0.482, 95% CI 0.379–0.612, <em>p</em> &lt; 0.0001). According to the results of our study, patients who had been treated with radiotherapy, chemotherapy, and surgery demonstrated longer survival than those who did not receive these treatment modalities, regardless of whether or not a propensity score matching process was performed.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373775_41598_2025_16890_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b5/12373775/a379aacb3b1d/41598_2025_16890_Fig2_HTML.jpg" loading="lazy" id="d33e967" height="426" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Survival curve of metastatic esophageal cancer before and after PSM. <strong>A</strong> Pre-PSM chemotherapy overall survival. <strong>B</strong> Post-PSM chemotherapy overall survival. <strong>C</strong> Pre-PSM radiotherapy overall survival. <strong>D</strong> Post-PSM radiotherapy overall survival. <strong>E</strong> Pre-PSM surgery overall survival. <strong>F</strong> Post-PSM surgery overall survival.</p></figcaption></figure></section><section id="Sec11"><h3 class="pmc_sec_title">Comparison of clinical case data between training and validation cohort</h3>
<p id="Par24">After eliminating baseline differences by the PSM method described above, a total of 1542 eligible patients were included, and we randomly divided the 1542 patients into a training cohort and a validation cohort according to the ratio of 7:3, in which 1116 patients were in the training cohort, and 426 patients were in the validation cohort. Among them, the case data of patients in the overall training cohort and validation cohort are shown in Table <a href="#Tab2" class="usa-link">2</a>.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Demographics and clinicopathological characteristics of patients with esophageal carcinoma.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Characteristics</th>
<th align="left" colspan="2" rowspan="1">All patients (<em>n</em> = 1542)</th>
<th align="left" colspan="2" rowspan="1">Training cohort (<em>N</em> = 1116)</th>
<th align="left" colspan="2" rowspan="1">Validation cohort (<em>N</em> = 426)</th>
<th align="left" rowspan="2" colspan="1">
<em>P</em> value</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">Number</th>
<th align="left" colspan="1" rowspan="1">%</th>
<th align="left" colspan="1" rowspan="1">Number</th>
<th align="left" colspan="1" rowspan="1">%</th>
<th align="left" colspan="1" rowspan="1">Number</th>
<th align="left" colspan="1" rowspan="1">%</th>
</tr>
</thead>
<tbody>
<tr><td align="left" colspan="8" rowspan="1">Sex</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Male</td>
<td align="left" colspan="1" rowspan="1">1288</td>
<td align="left" colspan="1" rowspan="1">83.5</td>
<td align="left" colspan="1" rowspan="1">931</td>
<td align="left" colspan="1" rowspan="1">83.4</td>
<td align="left" colspan="1" rowspan="1">357</td>
<td align="left" colspan="1" rowspan="1">83.8</td>
<td align="left" rowspan="2" colspan="1">0.857</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Female</td>
<td align="left" colspan="1" rowspan="1">254</td>
<td align="left" colspan="1" rowspan="1">16.5</td>
<td align="left" colspan="1" rowspan="1">185</td>
<td align="left" colspan="1" rowspan="1">16.6</td>
<td align="left" colspan="1" rowspan="1">69</td>
<td align="left" colspan="1" rowspan="1">16.2</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Race</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  White</td>
<td align="left" colspan="1" rowspan="1">1274</td>
<td align="left" colspan="1" rowspan="1">82.6</td>
<td align="left" colspan="1" rowspan="1">923</td>
<td align="left" colspan="1" rowspan="1">82.7</td>
<td align="left" colspan="1" rowspan="1">351</td>
<td align="left" colspan="1" rowspan="1">82.4</td>
<td align="left" rowspan="2" colspan="1">0.885</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Unwhite</td>
<td align="left" colspan="1" rowspan="1">268</td>
<td align="left" colspan="1" rowspan="1">17.4</td>
<td align="left" colspan="1" rowspan="1">193</td>
<td align="left" colspan="1" rowspan="1">17.3</td>
<td align="left" colspan="1" rowspan="1">75</td>
<td align="left" colspan="1" rowspan="1">17.6</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Age</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  &lt; 65 years</td>
<td align="left" colspan="1" rowspan="1">877</td>
<td align="left" colspan="1" rowspan="1">56.9</td>
<td align="left" colspan="1" rowspan="1">630</td>
<td align="left" colspan="1" rowspan="1">56.5</td>
<td align="left" colspan="1" rowspan="1">247</td>
<td align="left" colspan="1" rowspan="1">58.0</td>
<td align="left" rowspan="2" colspan="1">0.588</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  ≥ 65 years</td>
<td align="left" colspan="1" rowspan="1">665</td>
<td align="left" colspan="1" rowspan="1">43.1</td>
<td align="left" colspan="1" rowspan="1">486</td>
<td align="left" colspan="1" rowspan="1">43.5</td>
<td align="left" colspan="1" rowspan="1">179</td>
<td align="left" colspan="1" rowspan="1">42.0</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Marriage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Married</td>
<td align="left" colspan="1" rowspan="1">861</td>
<td align="left" colspan="1" rowspan="1">55.8</td>
<td align="left" colspan="1" rowspan="1">627</td>
<td align="left" colspan="1" rowspan="1">56.2</td>
<td align="left" colspan="1" rowspan="1">234</td>
<td align="left" colspan="1" rowspan="1">54.9</td>
<td align="left" rowspan="2" colspan="1">0.658</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Unmarried</td>
<td align="left" colspan="1" rowspan="1">681</td>
<td align="left" colspan="1" rowspan="1">44.2</td>
<td align="left" colspan="1" rowspan="1">489</td>
<td align="left" colspan="1" rowspan="1">43.8</td>
<td align="left" colspan="1" rowspan="1">192</td>
<td align="left" colspan="1" rowspan="1">45.1</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  None</td>
<td align="left" colspan="1" rowspan="1">478</td>
<td align="left" colspan="1" rowspan="1">31.0</td>
<td align="left" colspan="1" rowspan="1">351</td>
<td align="left" colspan="1" rowspan="1">31.5</td>
<td align="left" colspan="1" rowspan="1">127</td>
<td align="left" colspan="1" rowspan="1">29.8</td>
<td align="left" rowspan="2" colspan="1">0.534</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Yes</td>
<td align="left" colspan="1" rowspan="1">1064</td>
<td align="left" colspan="1" rowspan="1">69.0</td>
<td align="left" colspan="1" rowspan="1">765</td>
<td align="left" colspan="1" rowspan="1">68.5</td>
<td align="left" colspan="1" rowspan="1">299</td>
<td align="left" colspan="1" rowspan="1">70.2</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Radiotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  None</td>
<td align="left" colspan="1" rowspan="1">771</td>
<td align="left" colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">561</td>
<td align="left" colspan="1" rowspan="1">50.3</td>
<td align="left" colspan="1" rowspan="1">210</td>
<td align="left" colspan="1" rowspan="1">49.3</td>
<td align="left" rowspan="2" colspan="1">0.733</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Yes</td>
<td align="left" colspan="1" rowspan="1">771</td>
<td align="left" colspan="1" rowspan="1">50</td>
<td align="left" colspan="1" rowspan="1">555</td>
<td align="left" colspan="1" rowspan="1">49.7</td>
<td align="left" colspan="1" rowspan="1">216</td>
<td align="left" colspan="1" rowspan="1">50.7</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Histology</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">1032</td>
<td align="left" colspan="1" rowspan="1">66.9</td>
<td align="left" colspan="1" rowspan="1">751</td>
<td align="left" colspan="1" rowspan="1">67.3</td>
<td align="left" colspan="1" rowspan="1">281</td>
<td align="left" colspan="1" rowspan="1">66.0</td>
<td align="left" rowspan="2" colspan="1">0.619</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Non- adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">510</td>
<td align="left" colspan="1" rowspan="1">33.1</td>
<td align="left" colspan="1" rowspan="1">365</td>
<td align="left" colspan="1" rowspan="1">32.7</td>
<td align="left" colspan="1" rowspan="1">145</td>
<td align="left" colspan="1" rowspan="1">34.0</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Primary site</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Cervical/Upper</td>
<td align="left" colspan="1" rowspan="1">61</td>
<td align="left" colspan="1" rowspan="1">4.0</td>
<td align="left" colspan="1" rowspan="1">40</td>
<td align="left" colspan="1" rowspan="1">3.6</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">4.9</td>
<td align="left" rowspan="4" colspan="1">0.058</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Thoracic/middle</td>
<td align="left" colspan="1" rowspan="1">279</td>
<td align="left" colspan="1" rowspan="1">18.1</td>
<td align="left" colspan="1" rowspan="1">201</td>
<td align="left" colspan="1" rowspan="1">18.0</td>
<td align="left" colspan="1" rowspan="1">78</td>
<td align="left" colspan="1" rowspan="1">18.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Abdominal/lower</td>
<td align="left" colspan="1" rowspan="1">1119</td>
<td align="left" colspan="1" rowspan="1">72.6</td>
<td align="left" colspan="1" rowspan="1">805</td>
<td align="left" colspan="1" rowspan="1">72.1</td>
<td align="left" colspan="1" rowspan="1">314</td>
<td align="left" colspan="1" rowspan="1">73.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Overlapping</td>
<td align="left" colspan="1" rowspan="1">83</td>
<td align="left" colspan="1" rowspan="1">5.4</td>
<td align="left" colspan="1" rowspan="1">70</td>
<td align="left" colspan="1" rowspan="1">6.3</td>
<td align="left" colspan="1" rowspan="1">13</td>
<td align="left" colspan="1" rowspan="1">3.1</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Surgery</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  None</td>
<td align="left" colspan="1" rowspan="1">1459</td>
<td align="left" colspan="1" rowspan="1">94.6</td>
<td align="left" colspan="1" rowspan="1">1054</td>
<td align="left" colspan="1" rowspan="1">94.4</td>
<td align="left" colspan="1" rowspan="1">405</td>
<td align="left" colspan="1" rowspan="1">95.1</td>
<td align="left" rowspan="2" colspan="1">0.626</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Yes</td>
<td align="left" colspan="1" rowspan="1">83</td>
<td align="left" colspan="1" rowspan="1">5.4</td>
<td align="left" colspan="1" rowspan="1">62</td>
<td align="left" colspan="1" rowspan="1">5.6</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">4.9</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Grade</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  I + II</td>
<td align="left" colspan="1" rowspan="1">552</td>
<td align="left" colspan="1" rowspan="1">35.8</td>
<td align="left" colspan="1" rowspan="1">401</td>
<td align="left" colspan="1" rowspan="1">35.9</td>
<td align="left" colspan="1" rowspan="1">151</td>
<td align="left" colspan="1" rowspan="1">35.4</td>
<td align="left" rowspan="2" colspan="1">0.859</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  III + IV</td>
<td align="left" colspan="1" rowspan="1">990</td>
<td align="left" colspan="1" rowspan="1">64.2</td>
<td align="left" colspan="1" rowspan="1">715</td>
<td align="left" colspan="1" rowspan="1">64.1</td>
<td align="left" colspan="1" rowspan="1">275</td>
<td align="left" colspan="1" rowspan="1">64.6</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">T Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T1</td>
<td align="left" colspan="1" rowspan="1">414</td>
<td align="left" colspan="1" rowspan="1">26.8</td>
<td align="left" colspan="1" rowspan="1">295</td>
<td align="left" colspan="1" rowspan="1">26.4</td>
<td align="left" colspan="1" rowspan="1">119</td>
<td align="left" colspan="1" rowspan="1">27.9</td>
<td align="left" rowspan="5" colspan="1">0.620</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T2</td>
<td align="left" colspan="1" rowspan="1">84</td>
<td align="left" colspan="1" rowspan="1">5.4</td>
<td align="left" colspan="1" rowspan="1">66</td>
<td align="left" colspan="1" rowspan="1">5.9</td>
<td align="left" colspan="1" rowspan="1">18</td>
<td align="left" colspan="1" rowspan="1">4.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T3</td>
<td align="left" colspan="1" rowspan="1">390</td>
<td align="left" colspan="1" rowspan="1">25.3</td>
<td align="left" colspan="1" rowspan="1">285</td>
<td align="left" colspan="1" rowspan="1">25.5</td>
<td align="left" colspan="1" rowspan="1">105</td>
<td align="left" colspan="1" rowspan="1">24.6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  T4</td>
<td align="left" colspan="1" rowspan="1">399</td>
<td align="left" colspan="1" rowspan="1">25.9</td>
<td align="left" colspan="1" rowspan="1">291</td>
<td align="left" colspan="1" rowspan="1">26.1</td>
<td align="left" colspan="1" rowspan="1">108</td>
<td align="left" colspan="1" rowspan="1">25.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Tx</td>
<td align="left" colspan="1" rowspan="1">255</td>
<td align="left" colspan="1" rowspan="1">16.5</td>
<td align="left" colspan="1" rowspan="1">179</td>
<td align="left" colspan="1" rowspan="1">16.0</td>
<td align="left" colspan="1" rowspan="1">76</td>
<td align="left" colspan="1" rowspan="1">17.8</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">N Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  N0</td>
<td align="left" colspan="1" rowspan="1">417</td>
<td align="left" colspan="1" rowspan="1">27.0</td>
<td align="left" colspan="1" rowspan="1">299</td>
<td align="left" colspan="1" rowspan="1">26.8</td>
<td align="left" colspan="1" rowspan="1">118</td>
<td align="left" colspan="1" rowspan="1">27.7</td>
<td align="left" rowspan="3" colspan="1">0.684</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  N1</td>
<td align="left" colspan="1" rowspan="1">998</td>
<td align="left" colspan="1" rowspan="1">64.7</td>
<td align="left" colspan="1" rowspan="1">721</td>
<td align="left" colspan="1" rowspan="1">64.6</td>
<td align="left" colspan="1" rowspan="1">277</td>
<td align="left" colspan="1" rowspan="1">65.0</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Nx</td>
<td align="left" colspan="1" rowspan="1">127</td>
<td align="left" colspan="1" rowspan="1">8.2</td>
<td align="left" colspan="1" rowspan="1">96</td>
<td align="left" colspan="1" rowspan="1">8.6</td>
<td align="left" colspan="1" rowspan="1">31</td>
<td align="left" colspan="1" rowspan="1">7.3</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">M Stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  M1a</td>
<td align="left" colspan="1" rowspan="1">74</td>
<td align="left" colspan="1" rowspan="1">4.8</td>
<td align="left" colspan="1" rowspan="1">51</td>
<td align="left" colspan="1" rowspan="1">4.6</td>
<td align="left" colspan="1" rowspan="1">23</td>
<td align="left" colspan="1" rowspan="1">5.4</td>
<td align="left" rowspan="2" colspan="1">0.496</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  M1b</td>
<td align="left" colspan="1" rowspan="1">1468</td>
<td align="left" colspan="1" rowspan="1">95.2</td>
<td align="left" colspan="1" rowspan="1">1065</td>
<td align="left" colspan="1" rowspan="1">95.4</td>
<td align="left" colspan="1" rowspan="1">403</td>
<td align="left" colspan="1" rowspan="1">94.6</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Vital status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Alive</td>
<td align="left" colspan="1" rowspan="1">34</td>
<td align="left" colspan="1" rowspan="1">2.2</td>
<td align="left" colspan="1" rowspan="1">24</td>
<td align="left" colspan="1" rowspan="1">2.2</td>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">2.3</td>
<td align="left" rowspan="2" colspan="1">0.814</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Death</td>
<td align="left" colspan="1" rowspan="1">1508</td>
<td align="left" colspan="1" rowspan="1">97.8</td>
<td align="left" colspan="1" rowspan="1">1092</td>
<td align="left" colspan="1" rowspan="1">97.8</td>
<td align="left" colspan="1" rowspan="1">416</td>
<td align="left" colspan="1" rowspan="1">97.7</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par26">Of the 1542 patients with distant metastatic esophageal cancer, gender included 1288 male patients (83.5%) and 254 female patients (16.5%). Among races, there were 1274 cases of Caucasians, accounting for up to 82.6%, and 268 cases of non-Caucasians, accounting for 17.4%. Age &lt; 65 years had 877 patients (56.9%), and age ≥ 65 years had 665 patients (43.1%). In marriage, there were 861 patients (55.8%) who were married and 681 patients (44.2%) who were other (single, divorced, separated, widowed). Of chemotherapy, there were 1064 patients (69.0%) who received chemotherapy and 478 patients (31.0%) who did not receive chemotherapy. The number of patients who received radiotherapy and those who did not was 771 cases, accounting for 50%, and the histologic types were adenocarcinoma in 1032 cases, accounting for 66.9%, and non-adenocarcinoma in 510 cases, accounting for 33.1%. The tumor location was located in the upper EC in 61 cases, accounting for 4.0%, in the middle EC in 279 cases, accounting for 18.1%, in the lower EC in 1119 patients, accounting for 72.6%, and in the other patients in 83 cases, accounting for 5.4%. In surgical treatment, there were 1459 patients without surgery, accounting for 94.6%, and 83 patients with surgery, accounting for 5.4%. There were a total of 990 patients in grade III + IV tumor differentiation, accounting for 64.2%, and a total of 552 patients in grade I + II, accounting for 35.8%.There were 414 patients in the T1 stage in T staging, accounting for 26.8%, 84 patients in the T2 stage, accounting for 5.4%, 390 patients in the T3 stage, accounting for 25.3%, 399 patients in the T4 stage, accounting for 25.9%, 255 patients in Tx stage, accounting for 16.5%, and 417 patients in lymph node stage N0, accounting for 27.0%, 998 patients in N1, accounting for 64.7%, and 127 patients in Nx, accounting for 8.2%. Among distant metastases, there were 74 patients with M1a (4.8%) and 1468 patients with M1b (95.2%). A total of 1508 (97.8%) of the 1542 patients died, and 34 (2.2%) survived.</p>
<p id="Par27">The ROC curves for the 1-year, 2-year, and 3-year OS for in the study’s external validation group are shown in Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>. In the external validation group, we used the Kaplan–Meier survival curves to compare the effects of several combination treatment regimens (Supplementary Figs. <a href="#MOESM2" class="usa-link">2</a>A, B, <a href="#MOESM3" class="usa-link">3</a>A, B, <a href="#MOESM4" class="usa-link">4</a>A, B). Radiotherapy combined with chemotherapy showed a median OS of 8 months (95% CI 7.16–8.84 months, <em>p</em> &lt; 0.001), which was significantly superior to the 2 months observed in the radiotherapy-alone group (Supplementary Fig. <a href="#MOESM2" class="usa-link">2</a>A). The median OS reached 16 months (95% CI 7.70–24.30, <em>p</em> &lt; 0.001) in the radiotherapy combined with the surgery group, which was prolonged by 10 months compared with the radiotherapy alone group (Supplementary Fig. <a href="#MOESM2" class="usa-link">2</a>B). median OS was 14 months (95% CI 5.53–22.47, <em>p</em> &lt; 0.001) in the chemotherapy combined with surgery group, which was an improvement of 6 months compared with the chemotherapy alone group (Supplementary Fig. <a href="#MOESM3" class="usa-link">3</a>A). Median OS was 8 months in both groups for chemotherapy combined with radiotherapy and radiotherapy alone (<em>p</em> = 0.250). This result may be that radiotherapy is used for palliative radiotherapy in advanced metastatic esophageal cancer to alleviate painful symptoms (Supplementary Fig. <a href="#MOESM3" class="usa-link">3</a>B). Surgery combined with radiotherapy showed the median OS was 16 months (95% CI 7.70–24.30, <em>p</em> = 0.011), which was significantly better than the surgery alone group. This result suggests that postoperative radiotherapy may reduce the risk of recurrence (Supplementary Fig. <a href="#MOESM4" class="usa-link">4</a>A). Surgery combined with chemotherapy showed the Median OS was 14 months (95% CI 5.53–22.47, <em>p</em> = 0.032), but the sample size in the surgery alone group was too small (<em>n</em> ≈ 21) with a wide confidence interval (5–40 months) (Supplementary Fig. <a href="#MOESM4" class="usa-link">4</a>B).</p>
<p id="Par28">After statistical tests, it was found that there was no statistically significant difference between the training and validation cohort on the baseline balance (<em>p</em> &gt; 0.05), and the differences in the various study indicators were not statistically significant, see Table <a href="#Tab2" class="usa-link">2</a>. After plotting the OS survival curves for the training and validation cohort, it was found that there was also no statistically significant difference between the two groups (<em>p</em> = 0.77), and the detailed data are shown in Fig. <a href="#Fig3" class="usa-link">3</a>.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373775_41598_2025_16890_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b5/12373775/09407eae2a1f/41598_2025_16890_Fig3_HTML.jpg" loading="lazy" id="d33e1697" height="324" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier survival curve of comparison between training cohort and validation group.</p></figcaption></figure></section><section id="Sec12"><h3 class="pmc_sec_title">Independent prognostic factors in the training cohort</h3>
<p id="Par30">The results of univariate and multivariate Cox regression analysis are shown in Table <a href="#Tab3" class="usa-link">3</a>. Univariate Cox regression analysis was performed on all variables to explore the effects of different factors on the prognosis of metastatic esophageal cancer, and the results showed that “race, age, marriage, chemotherapy, radiotherapy, histological grading, tumor site, surgery, T stage, N stage, and M stage” were the prognostic factors affecting the OS of metastatic EC (<em>P</em> &lt; 0.05). In the multifactorial Cox risk proportional regression model, chemotherapy, radiotherapy, tumor site, surgery, T stage, and M stage were independent prognostic factors affecting OS in metastatic EC (Table <a href="#Tab3" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Univariate and multivariate Cox proportional hazards regression analysis in esophageal cancer patients.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Variables</th>
<th align="left" rowspan="2" colspan="1">HR comparison</th>
<th align="left" colspan="2" rowspan="1">Univariate analysis</th>
<th align="left" colspan="2" rowspan="1">Multivariable analysis</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">HR (95%CI)</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em> value</th>
<th align="left" colspan="1" rowspan="1">HR (95%CI)</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="2" colspan="1">Sex</td>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">1.091 (0.931–1.279)</td>
<td align="left" colspan="1" rowspan="1">0.280</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Race</td>
<td align="left" colspan="1" rowspan="1">White</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Unwhite</td>
<td align="left" colspan="1" rowspan="1">1.332 (1.138–1.559)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">1.034 (0.865–1.237)</td>
<td align="left" colspan="1" rowspan="1">0.711</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Age</td>
<td align="left" colspan="1" rowspan="1">&lt;65 years</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 65 years</td>
<td align="left" colspan="1" rowspan="1">1.170 (1.038–1.318)</td>
<td align="left" colspan="1" rowspan="1">0.010</td>
<td align="left" colspan="1" rowspan="1">1.122 (0.993–1.268)</td>
<td align="left" colspan="1" rowspan="1">0.064</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Marriage</td>
<td align="left" colspan="1" rowspan="1">Married</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Unmarried</td>
<td align="left" colspan="1" rowspan="1">0.817 (0.725–0.921)</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">1.097 (0.971–1.241)</td>
<td align="left" colspan="1" rowspan="1">0.138</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chemotherapy</td>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.338 (0.295–0.386)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">0.308 (0.266–0.357)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Radiotherapy</td>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.874 (0.776–0.985)</td>
<td align="left" colspan="1" rowspan="1">0.027</td>
<td align="left" colspan="1" rowspan="1">0.835 (0.740–0.942)</td>
<td align="left" colspan="1" rowspan="1">0.003*</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Histology</td>
<td align="left" colspan="1" rowspan="1">Adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Non-adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">1.274 (1.121–1.447)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">1.026 (0.876–1.203)</td>
<td align="left" colspan="1" rowspan="1">0.750</td>
</tr>
<tr>
<td align="left" rowspan="4" colspan="1">Primary site</td>
<td align="left" colspan="1" rowspan="1">Overlapping</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cervical/Upper</td>
<td align="left" colspan="1" rowspan="1">0.884 (0.596–1.312)</td>
<td align="left" colspan="1" rowspan="1">0.541</td>
<td align="left" colspan="1" rowspan="1">0.611 (0.407–0.918)</td>
<td align="left" colspan="1" rowspan="1">0.018</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Thoracic/middle</td>
<td align="left" colspan="1" rowspan="1">0.997 (0.757–1.313)</td>
<td align="left" colspan="1" rowspan="1">0.981</td>
<td align="left" colspan="1" rowspan="1">0.814 (0.612–1.082)</td>
<td align="left" colspan="1" rowspan="1">0.157</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Abdominal/lower</td>
<td align="left" colspan="1" rowspan="1">0.739 (0.576–0.947)</td>
<td align="left" colspan="1" rowspan="1">0.017</td>
<td align="left" colspan="1" rowspan="1">0.788 (0.612–1.015)</td>
<td align="left" colspan="1" rowspan="1">0.065</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Surgery</td>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.465 (0.353–0.614)</td>
<td align="left" colspan="1" rowspan="1">&lt;0.001</td>
<td align="left" colspan="1" rowspan="1">0.446 (0.333–0.596)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Grade</td>
<td align="left" colspan="1" rowspan="1">I + II</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">III + IV</td>
<td align="left" colspan="1" rowspan="1">1.124 (0.993–1.272)</td>
<td align="left" colspan="1" rowspan="1">0.066</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="5" colspan="1">T Stage</td>
<td align="left" colspan="1" rowspan="1">T1</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T2</td>
<td align="left" colspan="1" rowspan="1">0.770 (0.587–1.010)</td>
<td align="left" colspan="1" rowspan="1">0.059</td>
<td align="left" colspan="1" rowspan="1">0.879 (0.668–1.158)</td>
<td align="left" colspan="1" rowspan="1">0.360</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T3</td>
<td align="left" colspan="1" rowspan="1">0.814 (0.690–0.960)</td>
<td align="left" colspan="1" rowspan="1">0.015</td>
<td align="left" colspan="1" rowspan="1">0.956 (0.805–1.135)</td>
<td align="left" colspan="1" rowspan="1">0.607</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">T4</td>
<td align="left" colspan="1" rowspan="1">1.183 (1.004–1.394)</td>
<td align="left" colspan="1" rowspan="1">0.045</td>
<td align="left" colspan="1" rowspan="1">1.227 (1.038–1.451)</td>
<td align="left" colspan="1" rowspan="1">0.017</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tx</td>
<td align="left" colspan="1" rowspan="1">1.216 (1.008–1.467)</td>
<td align="left" colspan="1" rowspan="1">0.041</td>
<td align="left" colspan="1" rowspan="1">1.091 (0.894–1.333)</td>
<td align="left" colspan="1" rowspan="1">0.391</td>
</tr>
<tr>
<td align="left" rowspan="3" colspan="1">N Stage</td>
<td align="left" colspan="1" rowspan="1">N0</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">N1</td>
<td align="left" colspan="1" rowspan="1">0.959 (0.837–1.099)</td>
<td align="left" colspan="1" rowspan="1">0.548</td>
<td align="left" colspan="1" rowspan="1">1.044 (0.907–1.203)</td>
<td align="left" colspan="1" rowspan="1">0.546</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nx</td>
<td align="left" colspan="1" rowspan="1">1.490 (1.182–1.879)</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">1.226 (0.958–1.568)</td>
<td align="left" colspan="1" rowspan="1">0.105</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">M Stage</td>
<td align="left" colspan="1" rowspan="1">M1a</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">M1b</td>
<td align="left" colspan="1" rowspan="1">1.749 (1.303–2.349)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">1.799 (1.325–2.444)</td>
<td align="left" colspan="1" rowspan="1">&lt; 0.001</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p id="Par32">From the results of multifactorial Cox regression, we can learn that receiving chemotherapy was an independent prognostic factor for improving OS of metastatic EC compared with not receiving chemotherapy (HR = 0.038, 95% CI 0.266–0.357, <em>p</em> &lt; 0.001); receiving radiotherapy was also an independent prognostic factor for improving overall survival of metastatic EC compared with not receiving radiotherapy (HR = 0.835, 95% CI 0.740–0.942, <em>p</em> = 0.003); receiving surgery was also an independent prognostic factor for improving OS in distant metastatic EC compared to not receiving surgery (HR = 0.446, 95% CI 0.333–0.596, <em>p</em> &lt; 0.001); and in the upper esophagus (HR = 0.611,95% CI 0.407–0.918, <em>p</em> = 0.018) and lower esophagus (HR = 0.788, 95% CI 0.612–1.015, <em>p</em> = 0.065) had a poorer prognosis than patients with other tumor sites; patients with stage T4 (HR = 1.227, 95% CI 1.038–1.451, <em>p</em> = 0.017) had a poorer prognosis than patients with T1; patients with stage Nx (HR = 1.226,9 5% CI 0.958–1.568, <em>p</em> = 0.105) patients had a worse prognosis than N0 patients; M1b stage (HR = 1.799, 95% CI 1.325–2.444, <em>p</em> &lt; 0.001) patients had a worse prognosis than M1a stage patients (Table <a href="#Tab3" class="usa-link">3</a>).</p></section><section id="Sec13"><h3 class="pmc_sec_title">Prognostic nomogram for OS</h3>
<p id="Par33">The statistically significant study variables obtained from the multifactorial Cox regression analysis above, such as the six independent risk factors of radiotherapy, T-stage, M-stage, surgery, chemotherapy, and tumor site, were plotted on a column-line graph (Fig. <a href="#Fig4" class="usa-link">4</a>). The OS at 1 year, 2 years, and 3 years can be easily calculated, and the score value at the very top is the score obtained from the upwardly-directed vertical line made by each of the study variables below, and an individual risk score can be calculated by summing the scores obtained by all of them. The corresponding points were then found on the survival scale. The scores obtained can be summed to give a total score, an individual risk score is calculated, and the corresponding points are then found on the survival scale.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373775_41598_2025_16890_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b5/12373775/e283b84d2328/41598_2025_16890_Fig4_HTML.jpg" loading="lazy" id="d33e2101" height="604" width="669" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Nomogram predicting survival in patients with distant metastatic esophageal cancer.</p></figcaption></figure></section><section id="Sec14"><h3 class="pmc_sec_title">Calibration and validation of the nomogram</h3>
<p id="Par35">The accuracy and discriminative power of the column line drawings of distant metastatic EC could be evaluated based on C-index and AUC. In the prediction model, the C-index of OS in the training cohort was 0.690 (95% CI 0.672–0.709), and that of OS in the validation cohort was 0.659 (95% CI 0.627–0.693), and the AUCs of OS for metastatic EC in the training cohort for 1 year, 2 years, and 3 years were 69%, 73%, and 77.3%, respectively. The AUCs of 1, 2, and 3 years for OS of metastatic EC in the validation cohort were 69.4%, 73.4%, and 78.1%. The AUCs of 1, 2, and 3 years for OS of metastatic EC in the external validation cohort were 77.5%, 79.0%, and 80.4 (Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>). In the constructed model, the AUC values of the area under the curve for 1-year OS in the training cohort and validation cohort were between 0.50 and 0.70, and the AUCs of the rest of the training and validation cohorts were between 0.70 and 0.90, which indicated that the model had a medium degree of differentiation, and, it could be observed that the AUC of the area under the curve might get bigger and bigger with the prolongation of the time and that the predictive model was getting more and more reliable, and the prediction model was getting differentiation is getting stronger. The calibration curve showed a good agreement between the predictions of the risk model and the observed results, indicating that the model had good sensitivity and specificity (Supplementary Fig. <a href="#MOESM1" class="usa-link">1</a>). The ROC curves for the 1-year, 2-year, and 3-year OS for the training and validation cohort are shown in Fig. <a href="#Fig5" class="usa-link">5</a>. The calibration of the prediction model is assessed by the calibration curve, and the calibration curve is similar to the 45° diagonal line, which indicates that the calibration of the prediction model is good, and the calibration curves of the OS for 1, 2, and 3 years for the training and validation cohort are shown in Fig. <a href="#Fig6" class="usa-link">6</a>.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373775_41598_2025_16890_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b5/12373775/f19094b6c936/41598_2025_16890_Fig5_HTML.jpg" loading="lazy" id="d33e2147" height="382" width="669" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The ROC curves and AUCs at 1, 2, and 3 years in the training cohort and validation cohort. ROC curves for (<strong>A</strong>) 1-year, (<strong>B</strong>) 2-year, and (<strong>C</strong>) 3-year in the training cohort; and (<strong>D</strong>) 1 year, (<strong>E</strong>) 2 year, and (<strong>F</strong>) 3 years in the validation cohort. OS: overall survival.</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12373775_41598_2025_16890_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46b5/12373775/2a8ed621f2eb/41598_2025_16890_Fig6_HTML.jpg" loading="lazy" id="d33e2177" height="388" width="669" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Calibration curves predicting the 1-, 2-, and 3-year OS of patients in the training cohort and validation cohort. <strong>A</strong>, <strong>B</strong> and <strong>C</strong>: the training period is 1 year, 2 years, and 3 years; <strong>D</strong>, <strong>E</strong>, and <strong>F</strong>: the validation cohort is 1 year, 2 years, and 3 years;</p></figcaption></figure></section></section><section id="Sec15"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par38">EC remains an aggressive disease with a low survival rate<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a></sup>, with a low 5-year survival rate and distant metastases in 20–30% of patients with EC at initial diagnosis<sup><a href="#CR16" class="usa-link" aria-describedby="CR16">16</a></sup>. It is necessary to construct a prognostic model for metastatic esophageal cancer. Through univariate and multivariate Cox regression analysis, we found that radiotherapy, chemotherapy, surgery, tumor site, T-stage, and M-stage were independent risk factors affecting OS.</p>
<p id="Par39">Some studies have indicated that metastatic EC treated with surgery or radiotherapy can provide survival benefits for patients. Zhao et al. showed that the median survival of patients with M1a stage metastatic squamous EC undergoing R0 esophagectomy after simultaneous radiotherapy could reach 36.9 months<sup><a href="#CR17" class="usa-link" aria-describedby="CR17">17</a></sup>. Elk et al. found that after the use of a multimodal treatment approach, including surgery in patients with extraintestinal metastases or liver metastases from esophageal cancer, recurrence occurred in about 64% of R0 resection patients, and 50% of the operated patients were still alive after a median follow-up of 22 months<sup><a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup>. This suggests that palliative resection or radiotherapy may be beneficial for survival. There are also some case reports suggesting that a combination of treatments, such as surgery or radiotherapy treatment, improves the overall survival of patients with metastatic esophageal cancer<sup><a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>–<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup>. The above studies are consistent with the findings of the present study.</p>
<p id="Par40">Surgery is an option for earlier staging of esophageal cancer, and simultaneous radiochemotherapy is considered to be the preferred treatment option for locally advanced patients who are inoperable or unresectable. The results of a prospective phase II study showed that among patients with inoperable squamous esophageal cancer, those who received simultaneous radiotherapy with a chemotherapy regimen of cisplatin and doxorubicin had a more prolonged OS<sup><a href="#CR24" class="usa-link" aria-describedby="CR24">24</a></sup>. Seyedin et al. found that patients with non-visceral and non-osteosynovial metastatic EC who underwent radical radiotherapy in combination with surgery had a higher median OS than those who were treated with radiotherapy alone<sup><a href="#CR25" class="usa-link" aria-describedby="CR25">25</a></sup>. The results of the study conducted by David et al. showed that chemotherapy combined with radical radiotherapy improved the OS of patients even more<sup><a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup>. The results of the study in our SEER database also showed that radiotherapy improved the OS of patients with metastatic esophageal cancer.</p>
<p id="Par41">This study also has some limitations; the phase III study KEYNOTE-590 evaluated the efficacy of pembrolizumab in combination with chemotherapy as a first-line treatment for patients with advanced esophageal cancer<sup><a href="#CR26" class="usa-link" aria-describedby="CR26">26</a></sup>. ORIENT-15, also a phase III trial, compared to placebo in the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma, sindelizumab in combination with cisplatin in combination with paclitaxel showed significant benefits in terms of OS and progression-free survival<sup><a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>. In addition, similar benefits of sindilizumab in combination with cisplatin plus 5-fluorouracil showed significant potential<sup><a href="#CR27" class="usa-link" aria-describedby="CR27">27</a></sup>. The ESCORT-1st randomized clinical trial, a phase III trial designed to investigate the efficacy of chemotherapy combined with karelizumab treatment compared to placebo-combined chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma, demonstrated that the chemotherapy-combined karelizumab treatment group significantly improved patients’ OS and progression-free survival<sup><a href="#CR28" class="usa-link" aria-describedby="CR28">28</a></sup>. A multicenter phase III trial, the JUPITER-06 study, demonstrated that teraplizumab in combination with paclitaxel plus cisplatin chemotherapy significantly improved overall and progression-free survival in patients with primary advanced esophageal squamous carcinoma<sup><a href="#CR29" class="usa-link" aria-describedby="CR29">29</a></sup>. Cetuximab, targeting epidermal growth factor receptor (EGFR), and bevacizumab, targeting vascular endothelial growth factor (VEGF), have been shown to significantly improve the prognosis of patients with esophageal cancer<sup><a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a></sup>. Pabolizumab (PD-L1 inhibitor) has been approved for the treatment of patients with PD-L1-positive or advanced esophageal squamous cell carcinoma (ESCC), showing significant efficacy<sup><a href="#CR32" class="usa-link" aria-describedby="CR32">32</a></sup>.</p>
<p id="Par42">In contrast, the strategy of palliative chemotherapy combined with immunotherapy should be considered for those patients with distant metastatic disease<sup><a href="#CR7" class="usa-link" aria-describedby="CR7">7</a></sup>. For example, pembrolizumab combined with chemotherapy is used as first-line treatment for patients with advanced esophageal cancer. Immunotherapy is performed by activating one’s T-lymphocytes so that they recognize and kill tumor cells<sup><a href="#CR33" class="usa-link" aria-describedby="CR33">33</a></sup>. There are nationally renowned large clinical trials of immunotherapy for esophageal cancer, such as the study in KEYNOTE-028, which showed that pembrolizumab PD-L1-positive patients with advanced EC demonstrated manageable toxicity and continued to exhibit antitumor activity<sup><a href="#CR34" class="usa-link" aria-describedby="CR34">34</a></sup>. The study in CheckMate648 showed that in patients with advanced esophageal squamous cell carcinoma, either Nivolumab in combination with chemotherapy or in Nivolumab combination with ibritumomab as first-line treatment regimens both demonstrated significant benefits and were able to significantly prolong OS<sup><a href="#CR35" class="usa-link" aria-describedby="CR35">35</a></sup>. ATTRACTION-3, a phase III clinical trial, demonstrated that Nivolumab was associated with a significantly higher OS in patients with advanced esophageal squamous cell carcinoma who had received prior therapy compared to chemotherapy and a favorable safety profile<sup><a href="#CR36" class="usa-link" aria-describedby="CR36">36</a></sup>.</p>
<p id="Par43">There are also some limitations in this study, First, the SEER database does not contain information such as immunotherapy, targeted therapy, clinical manifestations, basic diseases, and surgical types. Second, although we consider chemotherapy in the nomogram, the specific scheme is unknown, different treatment schemes may lead to different results. In addition, we used SEER data mainly in America for validation and analysis but did not use data from patients in other countries. Therefore, the reliability of the findings would be higher if data from domestic and foreign multicenter studies were integrated for external validation.</p>
<p id="Par44">This study demonstrated that T-stage, M-stage, primary tumor site, surgery, chemotherapy, and radiotherapy are independent prognostic risk factors affecting the survival of patients with distant metastatic esophageal cancer. A study showed that the use of local therapy and local radiotherapy in oligometastatic EC patients proved to be beneficial for survival<sup><a href="#CR37" class="usa-link" aria-describedby="CR37">37</a></sup>. Again using the nomogram approach, this supports our findings. the nomogram can guide individualized management survival and provide valuable evidence for clinical decision-making<sup><a href="#CR38" class="usa-link" aria-describedby="CR38">38</a></sup>. Some studies have shown that age, gender, diagnostic grading, number of metastatic organs at the time of diagnosis, type of pathology, local treatment and chemotherapy are independent predictors of CSS in patients<sup><a href="#CR39" class="usa-link" aria-describedby="CR39">39</a></sup>. Our study did not find an effect of age, sex, and diagnostic grading on OS in distant metastatic esophageal cancer, which may be due to the heterogeneity of their selection of patients with initially diagnosed metastatic esophageal cancer. The majority of esophageal cancer diagnoses occur in the elderly. Additionally, We used propensity score matching (PSM) to effectively balance baseline differences caused by confounders such as age and gender. We nomogram can be utilized to design clinical trials for patients with metastatic esophageal cancer and to identify individuals eligible for trials of new therapies.</p>
<p id="Par45">The strength of our study lies in the selection of a large sample of metastatic EC patients and the adequate statistical analysis of a column line graph of distant metastatic EC patients, which has a better predictive effect on the prognosis of the patients and also has some clinical reference value. Moreover, with the continuous progress of immunotherapy and targeted therapies, the prediction of survival of cancer patients with different treatment combinations may be more challenging. Therefore, more multicenter studies and prospective data collection with other potential variables are needed to improve this column line graph.</p></section><section id="Sec16"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par46">We developed and validated a column-line diagram based on the SEER database, which can assist clinicians in predicting patient prognosis and also provide a convenient and reliable individualized survival prediction tool for patients with distant metastatic esophageal cancer. Our study demonstrated that T-stage, M-stage, primary tumor site, surgery, chemotherapy, and radiotherapy were independent prognostic risk factors affecting the survival of patients with distant metastatic esophageal cancer. Meanwhile, radiotherapy, chemotherapy, as well as surgical treatment can prolong the survival time of patients with distant metastatic esophageal cancer, which can bring survival benefits to patients with distant metastatic esophageal cancer.</p></section><section id="Sec17"><h2 class="pmc_sec_title">Supplementary Information</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM1_ESM.jpg" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (3.1MB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM2_ESM.jpg" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (1.7MB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM3_ESM.jpg" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 3</a><sup> (4.7MB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM4_ESM.png" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 4</a><sup> (3.1MB, png) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM5"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM5_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 5</a><sup> (19.9KB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>The authors thank all patients, especially for the ability to have open access to the SEER database.</p></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Shuang Li and Yanwei Lu wrote the main manuscript text, and Ruiqi Liu, Luanluan Huang and Ding Nan prepared Figs. 1, 2 and 3. Xiaoyan Chen and Wenjie Xia prepared Figs. 4 and 5. Xiaodong Liang and Haibo Zhang prepared Fig. 6. All the authors reviewed the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by grants from the National Natural Science Foundation of China (82473238 to Haibo Zhang; 82203377 to Yanwei Lu), Zhejiang natural science foundation of China (Grant num-ber: LQ22H160036, to Yanwei Lu; LY24H160022, to Haibo Zhang), Zhejiang Health Science and Technology Project (2025KY031 to Haibo Zhang).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>All data included in this study are available upon request by contact with the corresponding author.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar2"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par54">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Shuang Li, Yanwei Lu have contributed equally to this work.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Xiaodong Liang, Email: lxdctopone@sina.com.</p>
<p>Haibo Zhang, Email: zhbdoctor@163.com.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <em>CA Cancer J. Clin.</em><strong>71</strong> (3), 209–249 (2021).
</cite> [<a href="https://doi.org/10.3322/caac.21660" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33538338/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sung,%20H.%20et%20al.%20Global%20cancer%20statistics%202020:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries.%20CA%20Cancer%20J.%20Clin.71%20(3),%20209%E2%80%93249%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Zhu, H. et al. Esophageal cancer in china: Practice and research in the new era. <em>Int. J. Cancer</em>. <strong>152</strong> (9), 1741–1751 (2023).
</cite> [<a href="https://doi.org/10.1002/ijc.34301" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36151861/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu,%20H.%20et%20al.%20Esophageal%20cancer%20in%20china:%20Practice%20and%20research%20in%20the%20new%20era.%20Int.%20J.%20Cancer.%20152%20(9),%201741%E2%80%931751%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Chen, W. et al. Cancer statistics in china, 2015. <em>CA Cancer J. Clin.</em><strong>66</strong> (2), 115–132 (2016).
</cite> [<a href="https://doi.org/10.3322/caac.21338" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26808342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen,%20W.%20et%20al.%20Cancer%20statistics%20in%20china,%202015.%20CA%20Cancer%20J.%20Clin.66%20(2),%20115%E2%80%93132%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Liu, R. et al. Annexin A2 combined with TTK accelerates esophageal cancer progression via the akt/mtor signaling pathway. <em>Cell. Death Dis.</em><strong>15</strong> (4), 291 (2024).
</cite> [<a href="https://doi.org/10.1038/s41419-024-06683-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11043348/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38658569/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu,%20R.%20et%20al.%20Annexin%20A2%20combined%20with%20TTK%20accelerates%20esophageal%20cancer%20progression%20via%20the%20akt/mtor%20signaling%20pathway.%20Cell.%20Death%20Dis.15%20(4),%20291%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Yang, J. et al. Understanding esophageal cancer: The challenges and opportunities for the next decade. <em>Front Oncol.</em><strong>10</strong>, 1727 (2020).
</cite> [<a href="https://doi.org/10.3389/fonc.2020.01727" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7511760/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33014854/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang,%20J.%20et%20al.%20Understanding%20esophageal%20cancer:%20The%20challenges%20and%20opportunities%20for%20the%20next%20decade.%20Front%20Oncol.10,%201727%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Blot, W. J. Invited commentary: More evidence of increased risks of cancer among alcohol drinkers. <em>Am. J. Epidemiol.</em><strong>150</strong> (11), 1138 (1999).
</cite> [<a href="https://doi.org/10.1093/oxfordjournals.aje.a009939" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10588074/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Blot,%20W.%20J.%20Invited%20commentary:%20More%20evidence%20of%20increased%20risks%20of%20cancer%20among%20alcohol%20drinkers.%20Am.%20J.%20Epidemiol.150%20(11),%201138%20(1999)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>van Rossum, P. S. N., Mohammad, N. H., Vleggaar, F. P. &amp; van Hillegersberg, R. Treatment for unresectable or metastatic oesophageal cancer: Current evidence and trends. <em>Nat. Rev. Gastroenterol. Hepatol.</em><strong>15</strong> (4), 235–249 (2018).
</cite> [<a href="https://doi.org/10.1038/nrgastro.2017.162" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29235549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?van%20Rossum,%20P.%20S.%20N.,%20Mohammad,%20N.%20H.,%20Vleggaar,%20F.%20P.%20&amp;%20van%20Hillegersberg,%20R.%20Treatment%20for%20unresectable%20or%20metastatic%20oesophageal%20cancer:%20Current%20evidence%20and%20trends.%20Nat.%20Rev.%20Gastroenterol.%20Hepatol.15%20(4),%20235%E2%80%93249%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Tang, J. et al. CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer. <em>J. Adv. Res.</em><strong>61</strong>, 239 –2 51 (2024)
</cite> [<a href="https://doi.org/10.1016/j.jare.2023.09.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11258662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37734566/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tang,%20J.%20et%20al.%20CDK2-activated%20TRIM32%20phosphorylation%20and%20nuclear%20translocation%20promotes%20radioresistance%20in%20triple-negative%20breast%20cancer.%20J.%20Adv.%20Res.61,%20239%E2%80%89%E2%80%932%E2%80%8951%20(2024)" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Bleiberg, H. et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. <em>Eur. J. Cancer</em>. <strong>33</strong> (8), 1216–1220 (1997).
</cite> [<a href="https://doi.org/10.1016/s0959-8049(97)00088-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9301445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bleiberg,%20H.%20et%20al.%20Randomised%20phase%20II%20study%20of%20cisplatin%20and%205-fluorouracil%20(5-FU)%20versus%20cisplatin%20alone%20in%20advanced%20squamous%20cell%20oesophageal%20cancer.%20Eur.%20J.%20Cancer.%2033%20(8),%201216%E2%80%931220%20(1997)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Guttmann, D. M. et al. Improved overall survival with aggressive primary tumor radiotherapy for patients with metastatic esophageal cancer. <em>J. Thorac. Oncol.</em><strong>12</strong> (7), 1131–1142 (2017).
</cite> [<a href="https://doi.org/10.1016/j.jtho.2017.03.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28461255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guttmann,%20D.%20M.%20et%20al.%20Improved%20overall%20survival%20with%20aggressive%20primary%20tumor%20radiotherapy%20for%20patients%20with%20metastatic%20esophageal%20cancer.%20J.%20Thorac.%20Oncol.12%20(7),%201131%E2%80%931142%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Rusthoven, C. G. et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. <em>J. Clin. Oncol.</em><strong>34</strong> (24), 2835–2842 (2016).
</cite> [<a href="https://doi.org/10.1200/JCO.2016.67.4788" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27325855/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rusthoven,%20C.%20G.%20et%20al.%20Improved%20survival%20with%20prostate%20radiation%20in%20addition%20to%20androgen%20deprivation%20therapy%20for%20men%20with%20newly%20diagnosed%20metastatic%20prostate%20cancer.%20J.%20Clin.%20Oncol.34%20(24),%202835%E2%80%932842%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Dutton, S. J. et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial. <em>Lancet Oncol.</em><strong>15</strong> (8), 894–904 (2014).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(14)70024-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24950987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dutton,%20S.%20J.%20et%20al.%20Gefitinib%20for%20oesophageal%20cancer%20progressing%20after%20chemotherapy%20(COG):%20A%20phase%203,%20multicentre,%20double-blind,%20placebo-controlled%20randomised%20trial.%20Lancet%20Oncol.15%20(8),%20894%E2%80%93904%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Lee, S. &amp; Cohen, D. J. Pharmacotherapy for metastatic esophageal cancer: Where do we need to improve?. <em>Expert Opin. Pharmacother.</em><strong>20</strong> (3), 357–366 (2019).
</cite> [<a href="https://doi.org/10.1080/14656566.2018.1551881" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30526127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee,%20S.%20&amp;%20Cohen,%20D.%20J.%20Pharmacotherapy%20for%20metastatic%20esophageal%20cancer:%20Where%20do%20we%20need%20to%20improve?.%20Expert%20Opin.%20Pharmacother.20%20(3),%20357%E2%80%93366%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Yap, W-K. et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. <em>JAMA Netw. Open.</em><strong>1</strong> (6), e183242 (2018).
</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2018.3242" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6324455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30646236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yap,%20W-K.%20et%20al.%20Development%20and%20validation%20of%20a%20nomogram%20for%20assessing%20survival%20in%20patients%20with%20metastatic%20lung%20cancer%20referred%20for%20radiotherapy%20for%20bone%20metastases.%20JAMA%20Netw.%20Open.1%20(6),%20e183242%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Mao, W-M., Zheng, W-H. &amp; Ling, Z-Q. Epidemiologic risk factors for esophageal cancer development. <em>Asian Pac. J. Cancer Prev.</em><strong>12</strong> (10), 2461–2466 (2011).
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/22320939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mao,%20W-M.,%20Zheng,%20W-H.%20&amp;%20Ling,%20Z-Q.%20Epidemiologic%20risk%20factors%20for%20esophageal%20cancer%20development.%20Asian%20Pac.%20J.%20Cancer%20Prev.12%20(10),%202461%E2%80%932466%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Quint, L. E. et al. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. <em>Cancer</em><strong>76</strong> (7), 1120–1125 (1995).
</cite> [<a href="https://doi.org/10.1002/1097-0142(19951001)76:7&lt;1120::aid-cncr2820760704&gt;3.0.co;2-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8630886/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Quint,%20L.%20E.%20et%20al.%20Incidence%20and%20distribution%20of%20distant%20metastases%20from%20newly%20diagnosed%20esophageal%20carcinoma.%20Cancer76%20(7),%201120%E2%80%931125%20(1995)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Chao, Y-K. et al. Distant nodal metastases from intrathoracic esophageal squamous cell carcinoma: Characteristics of long-term survivors after chemoradiotherapy. <em>J. Surg. Oncol.</em><strong>102</strong> (2), 158–162 (2010).
</cite> [<a href="https://doi.org/10.1002/jso.21588" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20648587/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chao,%20Y-K.%20et%20al.%20Distant%20nodal%20metastases%20from%20intrathoracic%20esophageal%20squamous%20cell%20carcinoma:%20Characteristics%20of%20long-term%20survivors%20after%20chemoradiotherapy.%20J.%20Surg.%20Oncol.102%20(2),%20158%E2%80%93162%20(2010)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Van Daele, E. et al. Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer. <em>Acta Chir. Belg.</em><strong>118</strong> (4), 227–232 (2018).
</cite> [<a href="https://doi.org/10.1080/00015458.2017.1411557" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29258384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Van%20Daele,%20E.%20et%20al.%20Long-term%20survival%20after%20multimodality%20therapy%20including%20surgery%20for%20metastatic%20esophageal%20cancer.%20Acta%20Chir.%20Belg.118%20(4),%20227%E2%80%93232%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Tokairin, Y., Kumagai, Y. &amp; Yamazaki, S. A case of postoperative liver metastasis of esophageal cancer remains in progression free after successfully resected. <em>Gan Kagaku Ryoho</em>. <strong>36</strong> (12), 2462–2464 (2009).</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/20037456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tokairin,%20Y.,%20Kumagai,%20Y.%20&amp;%20Yamazaki,%20S.%20A%20case%20of%20postoperative%20liver%20metastasis%20of%20esophageal%20cancer%20remains%20in%20progression%20free%20after%20successfully%20resected.%20Gan%20Kagaku%20Ryoho.%2036%20(12),%202462%E2%80%932464%20(2009)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Ikebe, M., Kitamura, M., Saitoh, G. &amp; Hasegawa, H. Multimodality therapy containing hepatic arterial infusion chemotherapy for liver metastasis of esophageal cancer-a case report. <em>Gan Kagaku Ryoho</em>. <strong>39</strong> (10), 1555–1557 (2012).</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/23064071/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ikebe,%20M.,%20Kitamura,%20M.,%20Saitoh,%20G.%20&amp;%20Hasegawa,%20H.%20Multimodality%20therapy%20containing%20hepatic%20arterial%20infusion%20chemotherapy%20for%20liver%20metastasis%20of%20esophageal%20cancer-a%20case%20report.%20Gan%20Kagaku%20Ryoho.%2039%20(10),%201555%E2%80%931557%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Ida, S. et al. A case of recurrent esophageal cancer with lymph node and lung metastases, successfully treated with systemic chemotherapy and radiofrequency-ablation. <em>Gan Kagaku Ryoho</em>. <strong>39</strong> (1), 107–110 (2012).</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/22241362/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ida,%20S.%20et%20al.%20A%20case%20of%20recurrent%20esophageal%20cancer%20with%20lymph%20node%20and%20lung%20metastases,%20successfully%20treated%20with%20systemic%20chemotherapy%20and%20radiofrequency-ablation.%20Gan%20Kagaku%20Ryoho.%2039%20(1),%20107%E2%80%93110%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Iitaka, D. et al. Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: Report of a case. <em>Surg. Today</em>. <strong>43</strong> (5), 556–561 (2013).
</cite> [<a href="https://doi.org/10.1007/s00595-012-0240-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22752641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iitaka,%20D.%20et%20al.%20Case%20involving%20long-term%20survival%20after%20esophageal%20cancer%20with%20liver%20and%20lung%20metastases%20treated%20by%20multidisciplinary%20therapy:%20Report%20of%20a%20case.%20Surg.%20Today.%2043%20(5),%20556%E2%80%93561%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>St-Amour, P. et al. Correction to: The ‘’real R0’’: A resection margin smaller than 0.1 cm is associated with a poor prognosis after oncologic esophagectomy. <em>Ann. Surg. Oncol.</em><strong>28</strong> (Suppl 3), 882 (2021).
</cite> [<a href="https://doi.org/10.1245/s10434-021-10284-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9172763/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34115254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?St-Amour,%20P.%20et%20al.%20Correction%20to:%20The%20%E2%80%98%E2%80%99real%20R0%E2%80%99%E2%80%99:%20A%20resection%20margin%20smaller%20than%200.1%C2%A0cm%20is%20associated%20with%20a%20poor%20prognosis%20after%20oncologic%20esophagectomy.%20Ann.%20Surg.%20Oncol.28%20(Suppl%203),%20882%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Tang, H-R. et al. A phase II study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma. <em>Am. J. Clin. Oncol.</em><strong>39</strong> (4), 350–354 (2016).
</cite> [<a href="https://doi.org/10.1097/COC.0000000000000069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24732811/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tang,%20H-R.%20et%20al.%20A%20phase%20II%20study%20of%20concurrent%20chemoradiotherapy%20with%20paclitaxel%20and%20cisplatin%20for%20inoperable%20esophageal%20squamous%20cell%20carcinoma.%20Am.%20J.%20Clin.%20Oncol.39%20(4),%20350%E2%80%93354%20(2016)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Seyedin, S. N., Parekh, K. R., Ginader, T. &amp; Caster, J. M. The role of definitive radiation and surgery in metastatic esophageal cancer: An NCDB investigation. <em>Ann. Thorac. Surg.</em><strong>112</strong> (2), 459–466 (2021).
</cite> [<a href="https://doi.org/10.1016/j.athoracsur.2020.08.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33096068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Seyedin,%20S.%20N.,%20Parekh,%20K.%20R.,%20Ginader,%20T.%20&amp;%20Caster,%20J.%20M.%20The%20role%20of%20definitive%20radiation%20and%20surgery%20in%20metastatic%20esophageal%20cancer:%20An%20NCDB%20investigation.%20Ann.%20Thorac.%20Surg.112%20(2),%20459%E2%80%93466%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Kato, K. et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <em>Future Oncol.</em><strong>15</strong> (10), 1057–1066 (2019).
</cite> [<a href="https://doi.org/10.2217/fon-2018-0609" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30735435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kato,%20K.%20et%20al.%20KEYNOTE-590:%20Phase%20III%20study%20of%20first-line%20chemotherapy%20with%20or%20without%20pembrolizumab%20for%20advanced%20esophageal%20cancer.%20Future%20Oncol.15%20(10),%201057%E2%80%931066%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Lu, Z. et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double blind, phase 3 trial. <em>BMJ</em>. <strong>377</strong>, e068714 (2022).
</cite> [<a href="https://doi.org/10.1136/bmj-2021-068714" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9016493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35440464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lu,%20Z.%20et%20al.%20Sintilimab%20versus%20placebo%20in%20combination%20with%20chemotherapy%20as%20first%20line%20treatment%20for%20locally%20advanced%20or%20metastatic%20oesophageal%20squamous%20cell%20carcinoma%20(ORIENT-15):%20Multicentre,%20randomised,%20double%20blind,%20phase%203%20trial.%20BMJ.%20377,%20e068714%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Luo, H. et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. <em>JAMA</em>. <strong>326</strong> (10), 916–925 (2021).
</cite> [<a href="https://doi.org/10.1001/jama.2021.12836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8441593/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34519801/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo,%20H.%20et%20al.%20Effect%20of%20camrelizumab%20vs%20placebo%20added%20to%20chemotherapy%20on%20survival%20and%20progression-free%20survival%20in%20patients%20with%20advanced%20or%20metastatic%20esophageal%20squamous%20cell%20carcinoma:%20The%20ESCORT-1st%20randomized%20clinical%20trial.%20JAMA.%20326%20(10),%20916%E2%80%93925%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Wang, Z-X. et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. <em>Cancer Cell.</em>, <strong>40</strong>(3), 277 (2022).
</cite> [<a href="https://doi.org/10.1016/j.ccell.2022.02.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35245446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20Z-X.%20et%20al.%20Toripalimab%20plus%20chemotherapy%20in%20treatment-na%C3%AFve,%20advanced%20esophageal%20squamous%20cell%20carcinoma%20(JUPITER-06):%20A%20multi-center%20phase%203%20trial.%20Cancer%20Cell.,%2040(3),%20277%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Ruhstaller, T. et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: A randomized, open-label, phase III trial (SAKK 75/08). <em>Ann. Oncol.</em><strong>29</strong> (6), 1386–1393 (2018).
</cite> [<a href="https://doi.org/10.1093/annonc/mdy105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29635438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ruhstaller,%20T.%20et%20al.%20Neoadjuvant%20chemotherapy%20followed%20by%20chemoradiation%20and%20surgery%20with%20and%20without%20cetuximab%20in%20patients%20with%20resectable%20esophageal%20cancer:%20A%20randomized,%20open-label,%20phase%20III%20trial%20(SAKK%2075/08).%20Ann.%20Oncol.29%20(6),%201386%E2%80%931393%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Cunningham, D. et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK medical research Council ST03): Primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. <em>Lancet Oncol.</em><strong>18</strong> (3), 357–370 (2017).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(17)30043-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5337626/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28163000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cunningham,%20D.%20et%20al.%20Peri-operative%20chemotherapy%20with%20or%20without%20bevacizumab%20in%20operable%20oesophagogastric%20adenocarcinoma%20(UK%20medical%20research%20Council%20ST03):%20Primary%20analysis%20results%20of%20a%20multicentre,%20open-label,%20randomised%20phase%202%E2%80%933%20trial.%20Lancet%20Oncol.18%20(3),%20357%E2%80%93370%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Shah, M. A. et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. <em>JAMA Oncol.</em><strong>5</strong> (4), 546–550 (2019).
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.5441" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6459121/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30570649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shah,%20M.%20A.%20et%20al.%20Efficacy%20and%20safety%20of%20pembrolizumab%20for%20heavily%20pretreated%20patients%20with%20advanced,%20metastatic%20adenocarcinoma%20or%20squamous%20cell%20carcinoma%20of%20the%20esophagus:%20The%20phase%202%20KEYNOTE-180%20study.%20JAMA%20Oncol.5%20(4),%20546%E2%80%93550%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Yang, Y. Cancer immunotherapy: Harnessing the immune system to battle cancer. <em>J. Clin. Invest.</em><strong>125</strong> (9), 3335–3337 (2015).
</cite> [<a href="https://doi.org/10.1172/JCI83871" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4588312/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26325031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang,%20Y.%20Cancer%20immunotherapy:%20Harnessing%20the%20immune%20system%20to%20battle%20cancer.%20J.%20Clin.%20Invest.125%20(9),%203335%E2%80%933337%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Doi, T. et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. <em>J. Clin. Oncol.</em><strong>36</strong> (1), 61–67 (2018).
</cite> [<a href="https://doi.org/10.1200/JCO.2017.74.9846" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29116900/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Doi,%20T.%20et%20al.%20Safety%20and%20antitumor%20activity%20of%20the%20anti-programmed%20death-1%20antibody%20pembrolizumab%20in%20patients%20with%20advanced%20esophageal%20carcinoma.%20J.%20Clin.%20Oncol.36%20(1),%2061%E2%80%9367%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. <em>N Engl. J. Med.</em><strong>386</strong> (5), 449–462 (2022).
</cite> [<a href="https://doi.org/10.1056/NEJMoa2111380" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35108470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Doki,%20Y.%20et%20al.%20Nivolumab%20combination%20therapy%20in%20advanced%20esophageal%20squamous-cell%20carcinoma.%20N%20Engl.%20J.%20Med.386%20(5),%20449%E2%80%93462%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Kato, K. et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label, phase 3 trial. <em>Lancet Oncol.</em><strong>20</strong> (11), 1506–1517 (2019).
</cite> [<a href="https://doi.org/10.1016/S1470-2045(19)30626-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31582355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kato,%20K.%20et%20al.%20Nivolumab%20versus%20chemotherapy%20in%20patients%20with%20advanced%20oesophageal%20squamous%20cell%20carcinoma%20refractory%20or%20intolerant%20to%20previous%20chemotherapy%20(ATTRACTION-3):%20A%20multicentre,%20randomised,%20open-label,%20phase%203%20trial.%20Lancet%20Oncol.20%20(11),%201506%E2%80%931517%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Li, B. et al. Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases. <em>Sci. Rep.</em><strong>10</strong> (1), 11259 (2020).
</cite> [<a href="https://doi.org/10.1038/s41598-020-68160-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7347928/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32647289/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li,%20B.%20et%20al.%20Development%20and%20validation%20of%20a%20nomogram%20prognostic%20model%20for%20esophageal%20cancer%20patients%20with%20oligometastases.%20Sci.%20Rep.10%20(1),%2011259%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Jung, H. A. et al. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. <em>Cancer Res. Treat.</em><strong>45</strong> (4), 285–294 (2013).
</cite> [<a href="https://doi.org/10.4143/crt.2013.45.4.285" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3893326/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24454001/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jung,%20H.%20A.%20et%20al.%20Nomogram%20to%20predict%20treatment%20outcome%20of%20fluoropyrimidine/platinum-based%20chemotherapy%20in%20metastatic%20esophageal%20squamous%20cell%20carcinoma.%20Cancer%20Res.%20Treat.45%20(4),%20285%E2%80%93294%20(2013)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Tang, X. et al. A novel nomogram and risk classification system predicting the cancer-specific survival of patients with initially diagnosed metastatic esophageal cancer: A SEER-Based study. <em>Ann. Surg. Oncol.</em><strong>26</strong> (2), 321–328 (2019).
</cite> [<a href="https://doi.org/10.1245/s10434-018-6929-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30357578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tang,%20X.%20et%20al.%20A%20novel%20nomogram%20and%20risk%20classification%20system%20predicting%20the%20cancer-specific%20survival%20of%20patients%20with%20initially%20diagnosed%20metastatic%20esophageal%20cancer:%20A%20SEER-Based%20study.%20Ann.%20Surg.%20Oncol.26%20(2),%20321%E2%80%93328%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM1_ESM.jpg" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (3.1MB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM2_ESM.jpg" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 2</a><sup> (1.7MB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM3_ESM.jpg" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 3</a><sup> (4.7MB, jpg) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM4_ESM.png" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 4</a><sup> (3.1MB, png) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12373775/bin/41598_2025_16890_MOESM5_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 5</a><sup> (19.9KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>All data included in this study are available upon request by contact with the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Scientific Reports are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41598-025-16890-w"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41598_2025_Article_16890.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (3.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12373775/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12373775/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12373775%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12373775/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12373775/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12373775/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40846774/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12373775/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40846774/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12373775/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12373775/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="TZTYfrSMF8CNmZJXClv8eOwier0NTLlg6aCSHkiAqpi6Xbzhx3m2JKmTpN5Jg4wR">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
